# US 2023/0141347 A1 · Treatment of immune disorders

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0141347 A1
- Document ID: US20230141347A1
- Status: Published application
- Kind: A1
- Application number: 17/870,936
- Filed: 2022-07-22
- Published: 2023-05-11
- Earliest claimed: 2014-06-10
- Assignees: Mesoblast International Sarl
- Applicants: Mesoblast International Sarl
- Inventors: Silviu Itescu; Paul Simmons
- Web page: https://patentgrep.com/patent/US20230141347A1

## CPC

- A61K 35/28: Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 35/545: Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
- A61K 38/17: from animals; from humans {(enzyme inhibitors A61K38/005)}
- A61K 38/18: Growth factors; Growth regulators
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 3/06: Antihyperlipidemics
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 13/12: of the kidneys
- A61P 15/00: Drugs for genital or sexual disorders (for disorders of sex hormones A61P5/24); Contraceptives
- A61P 17/02: for treating wounds, ulcers, burns, scars, keloids, or the like
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 27/02: Ophthalmic agents
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present disclosure relates to stem cells which express high levels of Angeopoetin-1 (Ang1) and uses thereof in inhibiting M1-type macrophage production and treating inflammatory disease such as diabetes.

## Claims

### Claim at position 1

1-18. (canceled)

### Claim 19

A method of treating an inflammatory disease in a subject, the method comprising administering to the subject a composition comprising genetically unmodified stem cells wherein said genetically unmodified stem cells express vascular endothelial growth factor (VEGF) in an amount less than 0.05 μg/106 cells.

### Claim at position 3

20-23. (canceled)

### Claim 24 (depends on 19)

The method of claim 19, wherein said genetically unmodified stem cells are mesenchymal precursor cells.

### Claim 25 (depends on 19)

The method of claim 19, wherein said stem cells are mesenchymal stem cells.

### Claim at position 6

26-27. (canceled)

### Claim 28 (depends on 19)

The method of claim 19, wherein the method comprises administering about 0.1×106 to about 3×106 stem cells per kg to the subject.

### Claim at position 8

29-30. (canceled)

### Claim 31 (depends on 19)

The method of claim 19, wherein the method comprises administering about 2×106 stem cells per kg to the subject.

### Claim at position 10

32-35. (canceled)

### Claim 36 (depends on 19)

The method of claim 19, wherein the inflammatory disease is rheumatoid arthritis.

### Claim at position 12

37-48. (canceled)

### Claim 49 (depends on 19)

The method of claim 19, wherein said stem cells are administered intravenously.

### Claim 50 (depends on 19)

The method of claim 19, wherein said stem cells are administered over multiple doses.

### Claim at position 15

51-52. (canceled)

### Claim 53 (depends on 19)

The method of claim 19, wherein said genetically unmodified stem cells express vascular endothelial growth factor (VEGF) in an amount less than 0.03 μg/106 cells.

### Claim 54 (depends on 19)

The method of claim 19, wherein said genetically unmodified stem cells express vascular endothelial growth factor (VEGF) in an amount less than 0.02 μg/106 cells.
